Institut Fuer Praeventive Medizin & Klinische Forschung GbR
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Institut Fuer Praeventive Medizin & Klinische Forschung GbR, the Cardiovascular Diseases portfolio focuses on major heart and blood vessel conditions, including cardiovascular disease, hypertension, hypercholesterolemia, and risk reduction in people with elevated lipoprotein(a). The trials are designed to test new treatment approaches and assess whether they can better prevent serious cardiovascular events.
- Studies assessing whether new therapies can lower LDL-cholesterol and help patients reach individual lipid targets
- Research evaluating prevention of heart attack, urgent revascularization, and cardiovascular death in high-risk patients
- Trials exploring treatment strategies for people with type 2 diabetes, high blood pressure, and established cardiovascular disease
This work supports better control of long-term cardiovascular risk and aims to improve outcomes for patients who remain vulnerable despite standard care.
Immune System Diseases
The Immune System Diseases research at this site includes studies in rheumatoid arthritis, psoriatic arthritis, and non-radiographic axial spondyloarthritis. These trials mainly examine how well new treatments control inflammation, maintain remission, and reduce disease flares in people living with chronic autoimmune conditions.
- Trials testing whether treatment can sustain remission and prevent flare-ups in non-radiographic axial spondyloarthritis
- Studies evaluating symptom improvement and disease control in psoriatic arthritis
- Comparative research in rheumatoid arthritis focused on treatment safety and the risk of venous thromboembolism
The overall goal is to improve everyday disease management and help identify therapies that offer stronger and more durable control of immune-mediated inflammation.
Musculoskeletal Diseases
Research in Musculoskeletal Diseases at the Clinical Research Unit includes studies on chronic non-specific low back pain and inflammatory joint and spine disorders. These trials are focused on relieving pain, improving function, and finding more effective options for patients whose previous treatments have not provided enough benefit.
- Pain-focused research for chronic non-specific low back pain when standard non-opioid treatment has been insufficient
- Clinical studies in psoriatic arthritis and related inflammatory conditions affecting joints and mobility
- Treatment research aimed at reducing symptoms and improving quality of life in chronic musculoskeletal disorders
This area reflects a strong interest in both symptom relief and longer-term control of movement-limiting disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Amgen Inc.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Fuer Praeventive Medizin & Klinische Forschung GbR
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adaptive Phase 2a/2b Randomized Double-Blind Placebo-Controlled Trial of LY3871801 in Adults with Moderately-to-Severely Active Rheumatoid Arthritis | Eli Lilly & Co. | Phase II | Not Recruiting | Sep 2023 | Apr 2026 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2019-07-25 | 2019-07-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.